Skip To Main Content
C.H. Barrios on Muck Rack

C.H. Barrios

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with C.H.

Contact C.H., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆

|
By A. Gennari, F. Andre, Gustave Roussy, C.H. Barrios
| annalsofoncology.org
Acknowledgements MR is supported by an IH/ NCI Cancer Center Support Grant [grant number P30 CQA008748] and the Breast Cancer Research Foundation . SL is supported by the National Breast Cancer Foundation of Australia Endowed Chair and the Breast Cancer Research Foundation , New York. Manuscript editing support was provided by Claire Bramley and Jennifer Lamarre (ESMO Guidelines staff) and Angela Corstorphine of Kstorfin Medical Communications Ltd (KMC); this support was funded by ESMO .
Open in Who Shared Issue with article?

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

|
By S. Brae Adams, C.H. Barrios, Porto Alegre, L.A. Emens
| annalsofoncology.org
Highlights • Final OS data from IMpassion130 (A + nP in metastatic triple-negative breast cancer) agree with prior interim analyses. • OS benefit with A + nP versus P + nP in the ITT population was not statistically significant, precluding further testing. • Exploratory data not formally tested showed clinically meaningful OS benefit for A + nP in the PD-L1 IC-positive population. • Three-year OS rates in the PD-L1 IC-positive population were 35.8% with A + nP versus 22.2% with P + nP.
Open in Who Shared Issue with article?

VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC) - Annals of Oncology

|
By J. Huober, St. Gallen, C.H. Barrios, Porto Alegre
| annalsofoncology.org
Background PH + CT is standard of care for high-risk, HER2-positive EBC. PH activates antibody-dependent cellular cytotoxicity; combining A + PH + CT may restore anti-cancer immunity and further enhance activity. IMpassion050 (NCT03726879), a double-blind, randomised, placebo (PL)-controlled study, evaluated efficacy and safety of neoadj A/PL + PH + CT. We report the primary analysis. Methods Patients (pts) had T2–4, N1–3, M0 disease.
Open in Who Shared Issue with article?
See all 4 articles